Suppr超能文献

IB2 期、IIA 期大块宫颈癌的治疗:新辅助化疗后根治性子宫切除术和原发性根治性子宫切除术的单中心经验。

Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.

机构信息

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, 28 Yongun-dong, Jongno-gu, 110-744 Seoul, Korea.

出版信息

Arch Gynecol Obstet. 2011 Aug;284(2):477-82. doi: 10.1007/s00404-010-1685-9. Epub 2010 Sep 28.

Abstract

INTRODUCTION

The aim of this study was to compare the efficacy and safety of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (NAC group) with primary radical hysterectomy (RH group).

METHODS

We reviewed all patients with bulky stage IB-IIA cervical cancer treated at Seoul National University Hospital from January 1, 2000 to December 31, 2006. Thirty-three patients were treated with NAC prior to radical hysterectomy, and 41 patients were treated with radical hysterectomy.

RESULTS

Clinical characteristics were not significantly different between the two groups. The response rate in the NAC group was 81.8%. Operation time, estimated blood loss, and complication rate were not significantly different between the two groups. Pathologic outcomes were improved in the NAC group. Adjuvant therapy was less frequently performed in the NAC group (51.6%) than in the RH group (82.9%) (P = 0.005). The 5-year progression-free survival was 90.7% in the NAC group and 81.3% in the RH group, but the difference was not statistically significant (P = 0.297).

CONCLUSION

The results of this study suggest that NAC may improve pathologic outcomes, decrease the need for adjuvant radiation therapy and have a comparable operation feasibility without affecting progression-free survival.

摘要

简介

本研究旨在比较新辅助化疗(NAC)后行根治性子宫切除术(NAC 组)与直接行根治性子宫切除术(RH 组)的疗效和安全性。

方法

我们回顾了 2000 年 1 月 1 日至 2006 年 12 月 31 日期间在首尔国立大学医院接受治疗的所有局部晚期 IB-IIA 期宫颈癌患者。33 例患者接受 NAC 联合根治性子宫切除术治疗,41 例患者接受直接根治性子宫切除术治疗。

结果

两组患者的临床特征无显著差异。NAC 组的缓解率为 81.8%。两组的手术时间、估计失血量和并发症发生率无显著差异。NAC 组的病理结果得到改善。NAC 组(51.6%)辅助治疗的频率低于 RH 组(82.9%)(P = 0.005)。NAC 组的 5 年无进展生存率为 90.7%,RH 组为 81.3%,但差异无统计学意义(P = 0.297)。

结论

本研究结果表明,NAC 可能改善病理结果,减少辅助放疗的需求,并且具有可操作性,不会影响无进展生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验